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Abstract
Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the
treatment of choice for resectable peritoneal carcinomatosis (PC) and improved the survival of these patients. The
situation changes if PC recurs and repeated CRS with HIPEC is considered. The patient selection and outcome of
the repeated approach has not been well described. We analyzed our cohort and share the experiences.
Methods: Ninety-three CRS/HIPEC procedures, performed in 85 patients during the period 2001–2013, were
examined in a retrospective analysis. Type of primary, ECOG status, peritoneal cancer index (PCI), completeness of
cytoreduction (CC), duration of hospitalization, postoperative morbidity, mortality, and disease-free/overall survival
were reviewed.
Results: Six patients (7 %) underwent a second CRS/HIPEC (median interval between the two procedures:
26 months, range 8–61) including two patients with mesotheliomas, one patient with ovarian adenocarcinoma, one
patient with leiomyosarcoma of uterus, one patient with colon adenocarcinoma, and one patient with appendiceal
adenocarcinoma. The last two patients underwent a third CRS/HIPEC, 25 and 36 months, after the second
procedure. The median PCI was 14 (range, 4–26) during the first and 20 (range, 7–39) during the second CRS/HIPEC
of these patients. Completeness of cytoreduction score of 0 (CC-0) was achieved in all first procedures and in 67 %
of second procedures (CC-0; n = 4 and CC-1; n = 2). A CC-0 score was possible in both of the third procedures. The
mean operating time was 444 min (range, 198–642) and 427 min (range, 239–617) during the first and the second
procedure. Median intensive care unit (ICU) was 2 days, and hospital stay after second CRS/HIPEC was 17 days
(range, 7–50). The 30-day morbidity after repeated CRS/HIPEC was 33 % (16 % for grade III–IV complications), and
there was no 30-day mortality neither after the second nor after the third CRS/HIPEC. Median disease-free interval
between first CRS/HIPEC and peritoneal recurrence was 17 months (range, 8–30). Median disease-free survival of
18 months (range, 4–33) was achieved after the second CRS/HIPEC. After a median follow-up of 74 months (range,
39–151), all patients are alive with disease (n = 5) or disease free (n = 1) under chemotherapy.
Conclusions: In experienced centers, repeated CRS/HIPEC can be performed with safety. Patient selection and
correct timing is of particular importance in achieving control of the disease. Repeated CRS/HIPEC should be
considered as treatment option for selected patients with recurrent PC.
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Background
Peritoneal carcinomatosis (PC) had traditionally been
treated as part of palliative phase and resulted in a
poor prognosis with fatal disease progression. How-
ever, cytoreductive surgery (CRS) followed by hyper-
thermic intraperitoneal chemotherapy (HIPEC) has
nowadays been established as a treatment option for
this situation and remains important in the repertoire
of managing these patients [1, 2]. The principle
underlying this therapeutic modality is the complete
resection of all visible macroscopic peritoneal meta-
static disease, followed by the administration of
HIPEC, which provides higher local concentration of
the chemotherapeutic agents and additional cytotoxic
effect of the hyperthermia, resulting in treatment of
any residual, microscopic peritoneal disease [3, 4].
This procedure is indicated when peritoneal disease is
confirmed intra-abdominally and often used in peri-
toneal disease from appendiceal neoplasms, mesotheli-
omas, and ovarian or colorectal cancer, or even
gastric cancer, sarcomas, and primary peritoneal car-
cinoma [5–10].
Due to the progression of surgical technologies and
techniques, the morbidity and mortality rates of such
treatment approaches in high-volume centers have de-
creased accordingly with a corresponding increase in the
overall survival of selected patients with peritoneal sur-
face malignancies [6–12]. Multiple studies showed an ef-
fectiveness of CRS/HIPEC reporting that 5-year survival
rates for pseudomyxoma [6, 13–16], PC of colorectal
origin [7, 17, 18], PC of ovarian origin [8, 19, 20], and
peritoneal mesothelioma [10, 21, 22] ranges from 50 to
96 %, 22 to 51 %, 17 to 55 %, and 29 to 63 %,
respectively.
However, approximately 80 % of patients with PC of
colorectal origin, 24–44 % of patients with pseudomyx-
oma and 40 % of patients with mesothelioma recur alone
in the peritoneal cavity after CRS/HIPEC [13, 14, 23–
28]. In these cases, the option of a potentially curative
repeated CRS/HIPEC becomes a possible consideration.
However, limited data on outcomes and survival has
been published regarding recurrence of PC treated with
repeated CRS/HIPEC, and indications still remain
unclear.
The objective of the study is to perform a retro-
spective analysis of patients at our institution who
underwent repeated CRS/HIPEC as treatment of re-
current peritoneal carcinomatosis after primary CRS/
HIPEC. We aim to evaluate the utility and feasibility
of repeated CRS/HIPEC by recording the outcome,
morbidity, and mortality of the procedure proposing
that patients who undergo multiple CRS/HIPEC have
improved long-term outcomes with similar morbidity
and mortality to the first CRS/HIPEC.
Methods
Clinicopathological data and parameters and outcome
measures
A retrospective study of all patients who suffered recur-
rent disease after primary CRS/HIPEC and underwent
repeated CRS/HIPEC procedure at our institution was
conducted. Between 2001 and 2013, 93 CRS/HIPEC pro-
cedures were performed in 85 patients. Four patients
underwent two CRS/HIPEC and two patients underwent
three CRS/HIPEC procedures. Repeated CRS/HIPEC
was recommended for patients with histological evi-
dence or suspicion of recurrent peritoneal disease, based
on clinical, laboratory (elevated tumor markers: CEA,
CA125), and radiological examinations. These patients
were discussed at the multidisciplinary tumor board, and
the final decision was made by consensus, taking into
consideration the patients related variables as well as
parameter which could represent contraindications. The
patients’ selection criteria for repeated CRS/HIPEC are
shown in Table 1.
Patient data as age, race, gender, and ECOG-graded
functional status were reviewed. Furthermore, operative
variables as date of initial and repeat CRS/HIPEC, type
of primary malignancy, chemotherapeutic agent, hospital
and intensive care unit (ICU) length of stay, morbidity,
mortality, and disease-free and overall survival were re-
corded for each patient.
Τhe peritoneal cancer index (PCI), as previously de-
scribed by Sugarbaker, was used to determine the extent
of peritoneal disease. Completeness of cytoreduction
score (CC-score) was also recorded and was graded from
a score of 0–3, measuring the amount of disease left be-
hind after CRS [2, 29]. Surgical complications were de-
fined and classified as minor (grade 0/I/II) and major
(grade III/IV) according to Clavien-Dindo’s classification
of surgical complications [30]. Treatment-related mor-
tality was classified as death within 30 days of surgery
during hospitalization.
The follow-up period commenced at the date of initial
surgery with the censor date of December 2015. Two
disease-free survival (DFS) were computed: time from
initial CRS/HIPEC to first recurrence and time from
second-time CRS/HIPEC to second recurrence or end-
time of analysis (December 2015). Overall survival (OS)
was calculated from the date of initial CRS/HIPEC and
from the date of repeated CRS/HIPEC to the date of
death from any case or to the end-time of analysis.
CRS/HIPEC procedure
The treatment consisted of two elements: aggressive sur-
gical cytoreduction and HIPEC. All patients underwent
exploratory laparotomy, and CRS was performed as de-
scribed by Sugarbaker; it consists of six peritonectomy
procedures and resection of all macroscopic visible
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peritoneal disease aiming to attain a complete cytore-
duction (CC-0) [29]. The objective of repeated CRS/
HIPEC remained similar. Following the CRS procedure,
HIPEC was performed using closed technique for
60 min via the inflow and outflow catheters placed dur-
ing the operation. Chemotherapeutic agent was infused
in a body surface area-based (BSA-based) dose (mitomy-
cin C 20 mg/m2 or cisplatin 50 mg/m2) at 42 °C using
the hyperthermia pump. Mitomycin C was the drug of
choice for PC from primary colorectal and appendiceal
carcinoma, and cisplatin was the drug used when the
primary was ovarian carcinoma, sarcoma, peritoneal
mesothelioma, or primary peritoneal carcinoma. The
same agent was administrated in the first and the re-
peated CRS/HIPEC procedure as well. Patients were
monitored in the intensive care unit during the first
24 h of the postoperative period or until stabilization




From 2001 to 2013, six patients underwent repeated
CRS/HIPEC procedures for isolated peritoneal tumor re-
currence and were included in our study. These six pa-
tients represent a highly selected subset (7 %) from 85
patients who underwent totally 93 CRS/HIPEC proce-
dures. Seventy-nine patients did not undergo any iterative
CRS/HIPEC procedure because either they appeared no
recurrent peritoneal disease or they were not considered
to iterative CRS/HIPEC procedure. The distribution of
primaries in these 79 patients was as follows: colorectal
carcinoma (n = 29), pseudomyxoma (n = 11), appendiceal
(n = 9) and ovarian (n = 9) carcinoma, adenocarcinoma of
stomach (n = 9), mesothelioma (n = 5), primary peritoneal
serous papillary carcinoma (n = 3), small intestine cancer
(n = 2), ewing sarcoma (n = 1), and leiomyosarcoma of
uterus (n = 1).
Of 85 patients, a total of 25 patients (29.5 %) had a re-
current peritoneal disease after the first CRS/HIPEC
procedure in a median interval time of 20 months
(range, 3–58). Of these patients, 19 patients were not
considered to repeated/iterative CRS/HIPEC. The rea-
sons for exclusion were extraperitoneal or liver metasta-
ses (n = 10), disease considered to be unresectable upon
imaging (n = 7) with poor performance status (ECOG 2
or 3), CC-score of 2 during the laparotomy (n = 2), and
short bowel syndrome (n = 1).
Our high selected subset consisted of six patients. The
mean age of patients was 48 years (range, 16–64). There
were five females and one male patient. The primary tu-
mors were as follows: malignant peritoneal mesothelioma
(n = 2), ovarian carcinoma (n = 1), leiomyosarcoma of
uterus (n = 1), colon carcinoma (n = 1), and appendiceal
carcinoma (n = 1). The median interval time from diagno-
sis to first CRS/HIPEC was 15 months (range, 1–62), from
the first to second CRS/HIPEC was 26 months (8–61),
and from the second to third CRS/HIPEC was 30 months
(25–36, n = 2). Three patients did not receive preoperative
systemic chemotherapy before the first HIPEC, and a sys-
temic chemotherapy was not performed before the repeat
HIPEC in three patients.
HIPEC and perioperative parameters
The median PCI score during the first CRS/HIPEC was
14 (range, 4–26), and complete cytoreduction was
achieved for all six patients with a final cytoreduction
score of 0 (CC-0). During the second CRS/HIPEC, the
median PCI score was 21 (range, 11–39), and CC-0
cytoreduction was achieved in the majority of patients
(n = 4, 67 %); the other two patients were able to achieve
a CC-1 score. All patients undergoing a third CRS/
HIPEC (n = 2) achieved a CC-0 having a median PCI
score of 22 (range, 19–25).
Length of surgery tended to be shorter in those who
underwent repeated CRS/HIPEC 427 min (range, 239–
617) vs. 444 min (range, 198–642) in initial CRS/HIPEC,
although this was not statistically significant. In the third
CRS/HIPEC, the length of surgery was 711 min (range,
503–919). The required ICU time after first and second
Table 1 Patients’ selection criteria for repeated CRS/HIPEC
Inclusion criteria Exclusion criteria
Histologic or cytologic diagnosis of PC Extraperitoneal or liver metastases
Complete recovery from prior systemic chemotherapy or radiation treatments Poor performance status (ECOG 2–3)
Tolerance of initial HIPEC without major morbidity Multiple small bowel obstruction
Disease considered to be resectable based upon imaging Biliary obstruction
Good performance status (ECOG 0–1) Short bowel syndrome
Prior R0 or R1 resection during the first CRS Severe malnutrition
Maintain of nutritional reserves (albumin >3 g/dl) Short disease-free interval
Favorable tumor biology Class III appearance of the small bowel
Interval between two procedures of 6–12 months
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CRS/HIPEC was similar too (1.8 vs 1.6 days) whereas
median hospital stay on the surgical floor was 13 days
(range, 10–17) for first, 17 days (range, 7–50) for second,
and 26 days (range, 9–43) for third CRS/HIPEC proce-
dures, respectively, without any significant difference in
ICU and hospital stay time between initial and repeat
HIPEC.
In our study, two of our six patients developed
postoperative complications after the second CRS/
HIPEC showing a postoperative morbidity rate of
33 % whereas the morbidity of our complete patient
cohort (n = 85) after one CRS/HIPEC was 21 %. The
complications after the repeated CRS/HIPEC were as
follows: (a) renal failure (grade I), resolved after con-
servative treatment, and blood transfusion (grade II)
in the patient 1 and (b) enterocutaneous fistula with
intra-abdominal hemorrhage (grade III) in the pa-
tient 3, requiring relaparotomy; the patient was dis-
charged in good condition after a prolonged hospital
stay. Hence, the morbidity of major complications
requiring invasive or surgical management (grade III)
was 16 % (n = 1) in our case series study. There was
no postoperative mortality.
The details of all six patients are summarized in
Table 2.
Survival
Five patients (83 %) and four patients (67 %) received
adjuvant chemotherapy after initial and repeat HIPEC,
respectively. A median DFS (disease-free survival) of
18 months (range, 8–30) was achieved after initial CRS/
HIPEC till disease recurrence was detected. All patients
in this study cohort had a disease-free duration of at
least 6 months after the first CRS/HIPEC, and the ad-
ministrated chemotherapeutic agent was not replaced by
another agent. A median DFS of 18 months (range, 4–
33) was achieved after repeated procedure till second re-
current disease. Of the six patients of our study, five pa-
tients recurred after the second CRS/HIPEC with a
median disease-free interval (DFI) after the second CRS/
HIPEC of 14.8 months (range, 4–30), two of them (uter-
ine leiomyosarcoma, peritoneal mesothelioma) without a
direct avenue for further treatment. Two of the patients
who recurred after the second CRS/HIPEC (adenocar-
cinoma of colon, appendiceal carcinoma) underwent a
third CRS/HIPEC after 25 and 30 months, respectively.
The first patient received further chemotherapy after the
third CRS/HIPEC, was free of tumor for 16 months, and
at the last follow-up had a stable disease under chemo-
therapy. The second one received no chemotherapy after
the third CRS/HIPEC and was free of tumor for
Table 2 Summary table of treatment and outcomes of our cohort
Patient 1 2 3 4 5 6
Primary malignancy Colorectal Uterine sarcoma Mesothelioma Appendiceal Ovarian Mesothelioma
Gender F F M F F F
Age 52 64 60 48 48 16
First CRS/HIPEC
PCI score 4 21 26 16 10 11
CC score 0 0 0 0 0 0
Disease-free interval
(DFI), (months)




8 16 24 61 15 31
Second CRS/HIPEC
PCI score 7 27 22 39 20 11
CC score 0 0 0 1 1 0
Disease-free interval
(DFI) (months)
25 4 5 30 10 33
Overall survival since
initial CRS (months)
71 39 69 151 48 64
Overall survival since
second CRS (months)
63 23 43 102 33 33
Total number of CRS/
HIPEC
3 2 2 3 2 2















Alive, no evidence of
disease under
chemotherapy
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24 months till recurrent peritoneal metastases were di-
agnosed and treated by chemotherapy (at last follow-up
stable disease). Regarding the subgroup of patients (n = 79)
who did not undergo repeated CRS/HIPEC, the disease
(local recurrence and metastases)-free survival was
21.8 months (range, 3–104).
Median follow-up time (overall survival), which cap-
tures to death or last follow-up, was also recorded for
patients undergoing repeat HIPEC. The median follow-
up time from diagnosis of primary tumor for patients
undergoing repeat HIPEC was 89 months (range, 64–
152) and median follow-up since the first CRS/HIPEC
was 74 months (range, 39–151), whereas the median
follow-up time since the second CRS/HIPEC was
50 months (range, 33–102). To date, no patient was lost
to follow-up and all patients are still alive undergoing
chemotherapy treatment. Two patients had a stable dis-
ease, two patients progressive disease, and one patient
with disease regression; the last one remained free of dis-
ease under chemotherapy. The overall survival of the pa-
tients without treatment via repeated CRS/HIPEC (n = 79)
was 26.8 months (range, 3–108). To date, 45 patients were
alive (57 %), 27 died of disease (35.5 %), five died during
the hospital stay (postoperative mortality: 6 %), and one
was lost to follow-up (1.5 %).
Discussion
Peritoneal carcinomatosis (PC) cannot any longer be
considered as an unresectable, terminal metastatic dis-
ease since there is growing evidence that patients af-
fected by PC benefit from CRS/HIPEC procedure [6, 12,
21, 27]. But a subset of PC patients present with recur-
rent disease confined to the peritoneal cavity after the
first procedure which could be explained by the ad-
vanced stage of the disease at the time of diagnosis [24–
27]. Managing these patients is challenging with no
established protocols and no clear evidence of treatment
modalities for recurrent PC after primary CRS/HIPEC.
High-volume centers approach recurrent disease with
heterogeneous strategies, additive chemotherapy, radio-
therapy, iterative CRS (debulking), or repeated/iterative
CRS/HIPEC (iCRS/HIPEC) [23, 26], and there has been
a reasonable discussion regarding the tolerability of re-
peated CRS/HIPEC due to the extent of the operation
and the clinical and physiologic impact on the patient.
There have been a few studies noting improved long-
term overall survival for patients who underwent only
second-look surgery without HIPEC after the first CRS/
HIPEC procedure, compared to survival rate for patients
who did not receive second CRS procedure [31, 32].
Recently, repeated CRS/HIPEC has been also evalu-
ated in the setting of recurrent peritoneal disease in
some studies with variable results [24, 26, 27, 32–42];
but improved long-term survival was generally suggested
(Table 3). In our study of 85 patients, six patients (7 %)
were selected to undergo iCRS/HIPEC. This rate is com-
patible with the rates of other studies from specialized
centers (4–8 %) [24, 27, 33, 34]. However, Sugarbaker
et al. [43] and Chua et al. [35] reported the largest co-
horts of patients who were able to undergo a second
CRS/HIPEC (26 % 124/472 and 16 % 79/466, respect-
ively). This treatment option is performed and justified
in highly selected patients with an intention to achieve
further disease control and to prolong the survival of pa-
tients [32]. The patients we considered to be the best
candidates for a successful repeat cytoreduction are
those who filled out the criteria presented in Table 1,
such as completeness of initial cytoreduction, interval
between initial HIPEC and recurrence, and good func-
tional status. In our study, the CC-0 of all initial cytore-
ductions, the median interval of 26 months between the
two procedures, and the ECOG 0 status of patients mir-
ror the consideration of these criteria. These various
strict criteria and patient factors must be evaluated by
the multidisciplinary tumor board.
Repeated CRS/HIPEC is a technically feasible surgical
option but the risks of iterative procedures must be
carefully evaluated in addition to the potential survival
benefit. The morbidity rate of 33 % and the mortality
rate of 0 % in our series are comparable with that expe-
rienced in our patients undergoing an initial CRS/HIPEC
(21 and 1 %, respectively). Interestingly, the grade III/IV
morbidity is only 16 % (8 % after initial CRS/HIPEC)
which is one of the lowest reported in the literature
(Table 3), whereas no difference was observed in compli-
cation rates among patients treated with different HIPEC
regimens [24, 27, 33, 35].
In our study, two patients underwent three CRS/
HIPEC and both of them were free of tumor for 16 and
24 months, respectively, having a stable disease at the
last follow-up. Three or more CRS/HIPEC procedures
were already reported by other authors [32, 37]. Sardi
et al. reported four patients who underwent a third
CRS/HIPEC and a 1-year survival rate of 75 % [37],
similar to the 5-year OS of 70 % and a 10-year survival
of 53 % for patients undergoing three or more CRS/
HIPEC reported by Mohamed [44].
Our study also shows that systemic chemotherapy is
valuable as an additional single-treatment modality. We
suggest that systemic chemotherapy should always be
considered in addition to a secondary cytoreduction
since preoperative chemotherapy could help the selec-
tion of good candidates, improve the resectability rate of
PC, and decrease the recurrence rate after CRS/HIPEC.
However, there are currently no data to support this hy-
pothesis, and, in the present series, the sample size was
too small and the disease biology so variable to draw any
conclusion. At any case, a median overall survival of
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Table 3 Comparable illustration of studies’ results concerned clinical and survival parameters in repeated CRS/HIPEC
Study Number type of
primary


































5 Variousa n.a. n.a. n.a. n.a. 30 n.a. 0 n.a. n.a. 60 40 20
Brouquet
(2009) [24]
20 Variousb 6 n.a. 17j 15 60 30 5 63.2 n.a. 96 82 72.5
Saxena
(2010)[42]
40 Variousc n.a. 66 n.a. 32 80 35 2.5 n.a. n.a. n.a. n.a. n.a.
Golse (2012)
[33]
30 Variousd 8 90 22 15 73.3 40.5 3.3 18 140l n.a. n.a. n.a.
Votano poulos
(2012) [27]
62 Variouse 9 43.5 17j 7.5 48.4 33.3 3.2 60.8 32.3 78.7 48.6 31.6
Chua (2013)
[35]





23 65 23 11 n.a. 42 0 28 46.5 90.9 54.3 33.9
Wong
(2014)[36]
8 mesothelioma 13 100 15.6 8 50 25 0 56.7k 80k 100k 88k 64k
Iheme landu
(2015)[38]
44 mesothelioma 14 34.1 12.5 14 29.6 2.3 0 31k 54k n.a. 61k 46k
Vaira (2014)
[40]
16 Variousg n.a. n.a. 13j n.a. 43.7 18.7 n.a. n.a. n.a. n.a. n.a. n.a.
Wong (2015)
[39]




6 Variousi 6 100 25.8 17 33 16 0 50 50 100
n.a. not available
an.a.
bPseudomyxoma, colorectal (CRC), mesothelioma, carcinoid
cPseudomyxoma, CRC
dPseudomyxoma, CRC, mesothelioma, ovarian cancer, gastric cancer, cholangiocarcinoma, leiomyosarcoma, primary peritoneal carcinoma
eAppendiceal carcinoma, CRC, mesothelioma, ovarian cancer, gastric cancer, GIST, gallbladder carcinoma, small bowel carcinoma, leiomyosarcoma, urachal carcinoma
fPseudomyxoma, CRC, pseudomyxoma, appendiceal carcinoma, small bowel carcinoma, ovarian cancer, hepatocellular carcinoma
gPseudomyxoma, CRC, mesothelioma, ovarian cancer
hAppendiceal carcinoma, CRC, mesothelioma, ovarian cancer
iAppendiceal carcinoma, CRC, mesothelioma, ovarian cancer, uterine sarcoma
jMedian time till diagnosis of recurrent PC
kTime period estimating from first CRS/HIPEC













89 months (range, 64–152) from diagnosis was achieved
and all of our patients were alive during the last follow-
up remaining under control of disease through systemic
chemotherapy. Interestingly, the youngest patient of our
collective remained free of disease. This overall survival
of 100 % in our case series study mirrors the consider-
ation of strict selection criteria for repeated CRS/HIPEC,
the role of the additional systemic chemotherapy, and
the importance of early diagnosis of recurrence.
We must indeed highlight the importance of early
diagnosis of recurrence. Chua et al. [45] recently sug-
gested that careful follow-up for early detection of recur-
rence was an important requirement for management of
colorectal peritoneal metastases via iterative CRS/
HIPEC. We agree with this suggestion and believe that
patients should be surveyed with the appropriated im-
aging at regular intervals of 3–6 months within the ini-
tial 5 years when most disease recurrence for those with
PC would occur. This is to ensure that recurrences con-
fined to the peritoneal cavity are diagnosed when they
are still resectable and fairly low volume. In our series,
most cases of recurrence was diagnosed with CT scan
or/and serum tumor markers, in the absence of clinical
symptoms.
Multiple studies have shown that survival after initial
CRS/HIPEC was adversely influenced by different factors
such as increased PCI, incomplete CC, high ECOG, poor
nutrition, and histopathologic type of primary tumor [7,
18, 24, 32, 44–49]. However, there are no absolute inde-
pendent exclusion factors for iCRS/HIPEC procedures.
When evaluating the benefits of repeated CRS/HIPEC,
completion of cytoreduction indicated by CC score, dis-
tribution, and volume of PC as defined by PCI and inter-
val between the two procedures or even postoperative
complication are important factors in predicting and
prognosticating outcomes [12, 26, 28, 32, 38, 43]. Esqui-
vel et al. [32] demonstrated a negative impact on sur-
vival if the PCI score of iCRS/HIPEC is increased
supporting the use of iterative procedures in patients
with limited PC [26, 45, 48]. However, if the disease
could be removed completely, we often performed iCRS/
HIPEC despite high-volume disease. CC scores from the
initial CRS/HIPEC can also help identify patients for a
repeat procedure. Our policy is to perform iCRS/HIPEC
exclusively in patients with completely resected disease
(CC-0) in the initial CRS [26]. Furthermore, CC-0/1
scores from repeated CRS can have a profound effect on
outcome. If complete cytoreduction is deemed impos-
sible on the exploration of abdomen in the iCRS, an ag-
gressive intervention with HIPEC should be abandoned
and an alternative approach pursued [31, 32]. Our study
showed that a complete cytoreduction was feasible in
both procedures. However, the ability to achieve a
complete resection is dependent not only on tumor
histopathology and tumor extension but also on oper-
ator expertise and skill.
We recognize that this study has several limitations
since it has a small patient population and it is retro-
spective in nature. There is also a selection bias since
the patients offered for repeat procedures were highly
selected. Other confounding factors relate to the differ-
ent chemotherapeutic regimens and the role of the sys-
temic therapy on the behavior of isolated peritoneal
disease. We do not claim that our results can be applied
to every patient with peritoneal surface disease. How-
ever, we do believe that this treatment is feasible and
safe for high-selected patients.
Conclusions
In conclusion, our study proposes that repeated CRS/
HIPEC have meaningfully good long-term outcomes
with similar morbidity and mortality to that of initial
CRS/HIPEC. Selecting not only the correct patient but
also the correct timing to perform iterative procedures
in high-volume tertiary care centers with expertise in
the treatment of peritoneal surface disease is of para-
mount importance in achieving prolonged survival. Re-
peated CRS/HIPEC could be considered as treatment
option for highly selected patients with recurrent PC.
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